What is CRISPR Therapeutics's investing cash flow?

CRISPR Therapeutics (CRSP) reported investing cash flow of -$410.74M in Q1 2026.

How has CRISPR Therapeutics's investing cash flow changed year-over-year?

CRISPR Therapeutics's investing cash flow decreased by 1979.2% year-over-year, from -$19.76M to -$410.74M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

CRISPR Therapeutics CRSP Investing Cash Flow

Investing Cash Flow at other companies

Beam TherapeuticsBEAM

$25.27M+120%

Cogent Biosciences, Inc.COGT

-$36.46M-153%

CelcuityCELC

$34.52M+42.3%

Arrowhead ResearchARWR

-$894.28M-113%

Krystal Biotech, Inc.KRYS

-$63.58M-16.1%

Spyre Therapeutics, Inc.SYRE

$56.58M+92,856%

Other financials

Income statement

See full

Revenue$1.5M+68.6%

Operating income-$130.2M+12.2%

Net income-$122.9M+9.6%

EPS (diluted)-$1.28+19.0%

Balance sheet

See full

Cash & equivalents$423.3M+80.0%

Total debt$787.6M+259%

Total equity$1.8B-0.8%

Total assets$2.7B+25.8%

Cash flow

See full

Operating cash flow-$108.9M-102%

CapEx$504.0K+145%

Free cash flow-$109.4M-102%

Valuation

See full

Market cap$5.33B+56.4%

Profitability

See full

Operating margin-15,754.2%-17,253pp

Net margin-13,856.5%-15,058pp

FCF margin-9,777.6%-10,759pp

Returns & leverage

See full

Return on equity-31.2%+43.7pp

Debt / equity0.4×+0.3×

Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about CRISPR Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CRISPR Therapeutics's investing cash flow?: CRISPR Therapeutics (CRSP) reported investing cash flow of -$410.74M in Q1 2026.
How has CRISPR Therapeutics's investing cash flow changed year-over-year?: CRISPR Therapeutics's investing cash flow decreased by 1979.2% year-over-year, from -$19.76M to -$410.74M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.